Moderna’s mRNA-1010 Influenza Vaccine Phase 3 Trial Data Published in New England Journal of Medicine

Moderna recently announced the New England Journal of Medicine published the Phase 3 clinical safety and efficacy data for its investigational seasonal influenza vaccine, mRNA-1010. The study assessed the safety, reactogenicity, and efficacy of mRNA-1010 compared to currently available influenza vaccines.

The Phase 3 trial included a large participant group and the data indicated mRNA-1010 induced a significant immune response against influenza A strains and influenza B strains. Researchers also monitored the participants for adverse reactions, and the data showed the safety profile of mRNA-1010 was comparable to that of existing influenza vaccines. The findings suggest mRNA-1010 is a potentially effective and safe alternative for seasonal influenza prevention.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 6, 2026

Author

GOAI